Literature DB >> 20692633

Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.

Bridget Stuart1, Jenny H Lin, Peter J Mogayzel.   

Abstract

Pseudomonas aeruginosa (Pa) is the predominant organism infecting the airways of patients with cystic fibrosis (CF). This organism has an armamentarium of survival mechanisms that allows it to survive in the CF airway. Since colonization and chronic infection with Pa is associated with poorer lung function and increased morbidity and mortality, therapies that can prevent infection could significantly improve the lives of patients with CF. Numerous studies have examined the effects of treatment on the eradication of Pa as a means to ameliorate disease. This article outlines the pathophysiology and clinical implication of Pa acquisition, and reviews the existing treatment regimens aimed at early eradication of Pa in patients with CF. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20692633      PMCID: PMC4001925          DOI: 10.1016/j.prrv.2010.05.003

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  67 in total

1.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

2.  Effect of nebulizer type and antibiotic concentration on device performance.

Authors:  A Weber; G Morlin; M Cohen; J Williams-Warren; B Ramsey; A Smith
Journal:  Pediatr Pulmonol       Date:  1997-04

3.  Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  G Taccetti; S Campana; F Festini; M Mascherini; G Döring
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

4.  Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis.

Authors:  F Ratjen; G Comes; K Paul; H G Posselt; T O Wagner; K Harms
Journal:  Pediatr Pulmonol       Date:  2001-01

5.  Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease.

Authors:  Laura M Cobb; Josyf C Mychaleckyj; Daniel J Wozniak; Yolanda S López-Boado
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

6.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

7.  The influence of age on aerosol deposition in children with cystic fibrosis.

Authors:  H L Chua; G G Collis; A M Newbury; K Chan; G D Bower; P D Sly; P N Le Souef
Journal:  Eur Respir J       Date:  1994-12       Impact factor: 16.671

8.  Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.

Authors:  M Ballmann; P Rabsch; H von der Hardt
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

9.  Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.

Authors:  Miriam M Treggiari; Margaret Rosenfeld; Nicole Mayer-Hamblett; George Retsch-Bogart; Ronald L Gibson; Judy Williams; Julia Emerson; Richard A Kronmal; Bonnie W Ramsey
Journal:  Contemp Clin Trials       Date:  2009-01-15       Impact factor: 2.226

10.  Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

Authors:  A E Hollsing; M Granström; M L Vasil; B Wretlind; B Strandvik
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 11.677

View more
  31 in total

1.  Cystic fibrosis and the war for iron at the host-pathogen battlefront.

Authors:  Nicole M Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-22       Impact factor: 11.205

2.  [Management of multiresistant pathogens in urology].

Authors:  G Magistro; C Gratzke; C G Stief; W Weidner; F Wagenlehner
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

Review 3.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Amanda Plummer; Martin Wildman; Tim Gleeson
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

4.  Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis.

Authors:  Jodi E Gustave; Joseph A Jurcisek; Karen S McCoy; Steven D Goodman; Lauren O Bakaletz
Journal:  J Cyst Fibros       Date:  2012-11-17       Impact factor: 5.482

5.  KynR, a Lrp/AsnC-type transcriptional regulator, directly controls the kynurenine pathway in Pseudomonas aeruginosa.

Authors:  Claire A Knoten; L Lynn Hudson; James P Coleman; John M Farrow; Everett C Pesci
Journal:  J Bacteriol       Date:  2011-09-30       Impact factor: 3.490

6.  A Proof of Concept Study to Detect Urease Producing Bacteria in Lungs Using Aerosolized 13C-Urea.

Authors:  Hengameh H Raissy; Graham Timmins; Lea Davies; Theresa Heynekamp; Michelle Harkins; Zachary D Sharp; H William Kelly
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2016-06-01       Impact factor: 1.349

7.  A conserved suppressor mutation in a tryptophan auxotroph results in dysregulation of Pseudomonas quinolone signal synthesis.

Authors:  Claire A Knoten; Greg Wells; James P Coleman; Everett C Pesci
Journal:  J Bacteriol       Date:  2014-04-18       Impact factor: 3.490

8.  Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis.

Authors:  Florence Le Gall; Rozenn Le Berre; Sylvain Rosec; Jeanne Hardy; Stéphanie Gouriou; Sylvie Boisramé-Gastrin; Sophie Vallet; Gilles Rault; Christopher Payan; Geneviève Héry-Arnaud
Journal:  BMC Microbiol       Date:  2013-06-21       Impact factor: 3.605

9.  Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  Roger Sordé; Albert Pahissa; Jordi Rello
Journal:  Infect Drug Resist       Date:  2011-01-25       Impact factor: 4.003

10.  SNaPaer: a practical single nucleotide polymorphism multiplex assay for genotyping of Pseudomonas aeruginosa.

Authors:  Nadia Eusebio; Tiago Pinheiro; Adelina A Amorim; Fernanda Gamboa; Lucília Saraiva; Leonor Gusmão; António Amorim; Ricardo Araujo
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.